ConSynance Therapeutics is a clinical-stage biopharmaceutical company developing precision-dosed therapies for rare central nervous system (CNS) disorders with substantial unmet need.

​

Our lead program, CSTI-500, is an investigational, orally administered, serotonin-preferred triple monoamine reuptake inhibitor (TRI) with a concentration-dependent pharmacologic profile across the serotonin, dopamine, and norepinephrine systems. CSTI-500 is being evaluated in an ongoing U.S. Phase 2 clinical study in Prader-Willi syndrome (PWS), with a focus on behavioral dysregulation and hyperphagia. Our development approach combines human PET-informed exposure targets with individual pharmacokinetic measurements to support PK-guided dose selection.